NovaGenAI headquarters in Cyberjaya, Malaysia — where AI meets life sciences

// WHO WE ARE

WHERE AI MEETS LIFE SCIENCES

Founded to bring production-grade AI to enterprises across Southeast Asia.

Building the Future of Healthcare AI

NovaGenAI was founded with a singular vision: to bring production-grade artificial intelligence to enterprises across Southeast Asia. Born in healthcare and biotech — where data sovereignty, compliance, and precision are non-negotiable — we now bring that same rigour to every industry.

Our roots in healthcare taught us what enterprise AI really means: data that can't leak, workflows that can't fail, and compliance that's built in — not bolted on. We bring that same standard to finance, logistics, manufacturing, and beyond.

That's why we build AI systems purpose-designed for real businesses — deployed on-premise or cloud, multilingual by default, and production-ready from day one.

Our Mission

Our Mission

To deploy intelligent AI systems that transform business operations — making them faster, smarter, and more efficient — while maintaining the highest standards of data sovereignty and security.

Our Vision

Our Vision

A Southeast Asian business ecosystem where every organisation — from healthcare providers and biotech firms to logistics companies and financial institutions — has access to enterprise-grade AI that augments human capability and drives real results.

// LEADERSHIP

Our Team

DC

Don Calaki

Founder & CEO

AI strategy and product. Leading NovaGenAI's mission to deploy production AI systems across enterprises through intelligent agents and on-premise infrastructure.

JT

James Then Khong Lek

Board Director

CEO/MD of CryoCord Group, representative of the Malaysian Association of Cell & Gene Therapy (MACGT). Decades of leadership in stem cell banking.

HL

Henry Low

Board Director

CryoCord Group Board member. Bringing corporate governance expertise and strategic oversight to NovaGenAI's growth trajectory.

CSK

Prof Dato' Dr. Cheong Soon Keng

Scientific Advisor

UKM Emeritus Professor of Haematology, Fellow of the Academy of Sciences Malaysia (FASc). 344+ publications. Co-founder of CryoCord. Bridging scientific rigour with AI innovation.

// STRATEGIC PARTNERS

Our Partners

Partner Programs

Member of the world's most prestigious technology partner ecosystems

NVIDIA Inception Program NVIDIA Inception Applied
Google Cloud Partner Network Google Cloud Partner Applied
AMD AI Developer Program AMD AI Developer Active Member
AWS Partner Network AWS Partner Network Upcoming
Microsoft for Startups Microsoft for Startups Upcoming
65%
Market Share Client
Powering Malaysia's largest stem cell bank
3
Languages Supported
English, Bahasa Malaysia, Mandarin
On-Prem
AI Capability
NVIDIA DGX Spark infrastructure

Frequently Asked Questions

NovaGenAI Sdn. Bhd. is an enterprise AI systems company headquartered in Cyberjaya, Malaysia. Founded in November 2025, we design, build, and deploy production-grade AI systems for enterprises across Southeast Asia, Australia, and beyond. Our specialisations include autonomous AI agents, computational biotech intelligence, LLM engineering, and on-premise AI infrastructure.
NovaGenAI is headquartered at Suite 1-1, 1st Floor, Bio-X Centre, Persiaran Cyberpoint Selatan, Cyber 8, 63000 Cyberjaya, Selangor, Malaysia. We serve clients across Malaysia, Singapore, Australia, and the broader Asia-Pacific region.
NovaGenAI was founded by Don Calaki, who serves as CEO. Don brings deep expertise in AI infrastructure, computational biotech, and enterprise AI deployment. The leadership team also includes John Olino as CFO.
NovaGenAI serves enterprises across multiple industries including healthcare and biotech, financial services, manufacturing, defence, and government. Our solutions are particularly relevant for regulated industries that require data sovereignty and on-premise AI deployment.
NovaGenAI is backed by MerakInvestments, CryoCord Group, and Brighton Healthcare Group. The company is currently raising a $1M seed round to accelerate product development and market expansion across Asia-Pacific.